Zobrazeno 1 - 10
of 244
pro vyhledávání: '"Lee‐Jen Wei"'
Autor:
Edoardo Gronda, Maurizio Gallieni, Giuseppe Pacileo, Giovambattista Capasso, Lee-Jen Wei, Francesco Trepiccione, Marco Heidempergher, Mario Bonomini, Marco Zimarino, José Carolino Divino-Filho, Lorenzo Di Liberato, Maria Michela Caracciolo, Valentina Masola, Tommaso Prosdocimi, Massimo Iacobelli, Caterina Vitagliano, Arduino Arduini
Publikováno v:
Kidney & Blood Pressure Research (2024)
Introduction: Peritoneal Ultrafiltration (PUF) has been proposed as an additional therapeutic option for Refractory Congestive Heart Failure (RCHF) patients. Despite promising observational studies and/or case report results, limited clinical trials
Externí odkaz:
https://doaj.org/article/a7d94e43ca73456eb6fc734abb05e0ee
Autor:
Annalisa Ruggeri, Francesco Corrado, Antonio Voza, Lee-Jen Wei, Gloria Catalano, Carmine Liberatore, Rosamaria Nitti, Carlo Fedeli, Alessandro Bruno, Eleonora Calabretta, Fabio Giglio, Fabio Sciutti, Francesca Lunghi, Giovanni Landoni, Alessio Aghemo, Massimo Iacobelli, Patrizia Rovere Querini, Paul G. Richardson, Andrea Assanelli, Jacopo Peccatori, Fabio Ciceri, Carmelo Carlo-Stella
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The coronavirus disease 2019 (COVID-19) pandemic led to an unprecedented burden on healthcare systems around the world and a severe global socioeconomic crisis, with more than 750 million confirmed cases and at least 7 million deaths reported by 31st
Externí odkaz:
https://doaj.org/article/e626a6cf241d4feb8370a979f32275f0
Autor:
Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A. Dimopoulos, Philippe Moreau, David Dingli, Lee‐Jen Wei, Joshua Richter, Noa Biran, David Siegel, William Reichmann, Lingling Li, Shijie Tang, Jean‐Richard Saint‐Martin, Anita Joshi, Michael Kauffman, Jatin Shah, Sharon Shacham, Sagar Lonial
Publikováno v:
eJHaem, Vol 2, Iss 1, Pp 48-55 (2021)
Abstract Triple‐class‐refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low‐dose de
Externí odkaz:
https://doaj.org/article/dc57c040186644f69a2171ddea55b3db
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/cb5cbe0842d74bedb6574c551ec26a4f
Publikováno v:
BMJ Open, Vol 11, Iss 9 (2021)
Background Restricted mean survival time analysis offers an intuitive and robust summary of treatment effect compared with HRs.Objective To examine the effect of intensive versus standard blood pressure (BP) control on death or cardiovascular events
Externí odkaz:
https://doaj.org/article/47f606ed1fc8429ca27ab3d6536db96a
Autor:
LaRowe, Lisa R., Miaskowski, Christine, Miller, Angela, Mayfield, Andrea, Keefe, Francis J., Smith, Alexander K., Cooper, Bruce A., Lee-Jen Wei, Ritchie, Christine S.
Publikováno v:
Nursing Research; Jan/Feb2024, Vol. 73 Issue 1, p81-88, 8p
Autor:
Dae Hyun Kim, Curtis Tatsuoka, Zhengyi Chen, Jackson T. Wright, Michelle C. Odden, Srinivasan Beddhu, Brandon K. Bellows, Adam Bress, Thaddeus Carson, William C. Cushman, Karen C. Johnson, Donald E. Morisky, Henry Punzi, Leonardo Tamariz, Song Yang, Lee-Jen Wei
Publikováno v:
Journal of General Internal Medicine. 37:3797-3804
Communication of the benefits and harms of blood pressure lowering strategy is crucial for shared decision-making.To quantify the effect of intensive versus standard systolic blood pressure lowering in terms of the number of event-free days DESIGN: P
Autor:
Pardeep S. Jhund, Brian L. Claggett, Atefeh Talebi, Jawad H. Butt, Samvel B. Gasparyan, Lee-Jen Wei, Zachary R. McCaw, Ulrica Wilderäng, Olof Bengtsson, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Muthiah Vaduganathan, Scott D. Solomon, John J. V. McMurray
Publikováno v:
JAMA Cardiology.
ImportanceIn the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in p
Publikováno v:
Journal of Clinical Oncology. 41:1952-1953
Autor:
Ryan, Sun, Lee-Jen, Wei
Publikováno v:
The New England journal of medicine. 387(15)